Lead Product(s) : Sulcardine Sulfate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Huyabio Presents Positive Phase 2a Results for HBI-3000 in Atrial Fibrillation
Details : HBI-3000 (Sulcardine Sulfate) is a multi-ion channel blocker, it inhibits INa-Peak, INa-Late, ICa,L, and IKr, with dominant effects on late sodium current (INa-L) to reduce proarrhythmic risks.
Product Name : HBI-3000
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 24, 2025
Lead Product(s) : Sulcardine Sulfate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : HRS-5346
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Merck & Co
Deal Size : $1,970.0 million
Deal Type : Licensing Agreement
Merck Licenses HRS-5346, Oral Lipoprotein(a) Inhibitor, from Jiangsu Hengrui
Details : Under the licensing agreement, Merck will hold the rights of HRS-5346, an investigational oral small molecule Lp(a), inhibitor currently being evaluated in a Phase 2 clinical trial in China.
Product Name : HRS-5346
Product Type : Other Small Molecule
Upfront Cash : $200.0 million
March 25, 2025
Lead Product(s) : HRS-5346
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Merck & Co
Deal Size : $1,970.0 million
Deal Type : Licensing Agreement
Lead Product(s) : DR10624
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Doer Biologics Completes Enrollment of the Phase 2 Clinical Study of DR10624
Details : DR10624 is first-in-class, tri-specific agonist targeting FGF21R, GCGR, GLP-1R. It is being evaluated for the treatment of severe hypertriglyceridemia.
Product Name : DR10624
Product Type : Protein
Upfront Cash : Inapplicable
March 09, 2025
Lead Product(s) : DR10624
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DR10624
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Doer Biologics Doses First Patient in Phase 2 Study of DR10624 for Hypertriglyceridemia
Details : DR10624 is a novel FIC tri-specific biotherapeutic that specifically agonizing GLP-1R, glucagon receptor GCGR & FGF21R, it is being investigated for the treatment of obesity and hypertriglyceridemia.
Product Name : DR10624
Product Type : Protein
Upfront Cash : Inapplicable
September 30, 2024
Lead Product(s) : DR10624
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Vicagrel
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Jiangsu Vcare Files NDA for Vicagrel Capsules with US FDA
Details : Vicagrel is an oral small molecule, P2Y12 receptor antagonist, which is under phase 2 clinical developmet for the treatment of coronary artery diseases.
Product Name : Vicagrel
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 01, 2024
Lead Product(s) : Vicagrel
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sulcardine Sulfate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Huyabio International Announces Initiation Of Hbi-3000 Phase 2 Trial
Details : The drug's preclinical and clinical pharmacology supports the potential of HBI-3000 (sulcardine sulfate) to restore sinus rhythm in Atrial Fibrillation. The drug has demonstrated a low risk for proarrhythmia in preclinical testing.
Product Name : HBI-3000
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 14, 2022
Lead Product(s) : Sulcardine Sulfate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sulcardine Sulfate
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The drug’s preclinical and clinical pharmacology supports the potential of HBI-3000 to restore sinus rhythm in Atrial Fibrillation. The drug has demonstrated a low risk for proarrhythmia in preclinical testing.
Product Name : HBI-3000
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 17, 2022
Lead Product(s) : Sulcardine Sulfate
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable